Drug intelligence / Profile preview

ertapenem + metronidazole + cefdinir

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral, Topical
01

Overview

This is a combination of three antibiotics—ertapenem, metronidazole, and cefdinir—each with distinct mechanisms of action. Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa; it disrupts DNA synthesis in susceptible organisms. Cefdinir is an oral third-generation cephalosporin that also inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins but has a different spectrum of activity compared to ertapenem. This combination would provide broad-spectrum coverage against aerobic Gram-positive and Gram-negative bacteria (ertapenem, cefdinir) as well as anaerobes (metronidazole). Such combinations are sometimes used or considered for complicated intra-abdominal infections or other polymicrobial infections where broad coverage is needed[1][4][6][7].

02

Targets

PBP (Penicillin-binding protein family)Neuraminidase

Beyond the preview

Go deeper on ertapenem + metronidazole + cefdinir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ertapenem + metronidazole + cefdinir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call